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Highlights 16 
 A category of saturated alcohols was created 17 
 Data compilation was undertaken for the category of n-alkanaols 18 
 Repeat dose NOELs were read across for low toxicity compounds 19 
 In vitro data reduce uncertainty in read-across 20 
  21 
Abstract: n-Alkanols provide an excellent example where a category-approach to read-across 22 
may be used to estimate the repeated-dose endpoint for a number of untested derivatives (target 23 
chemicals) using experimental data for tested derivatives (source chemicals). n-Alkanols are 24 
non-reactive and exhibit the unspecific, reversible simple anaesthesia or non-polar narcosis mode 25 
of toxic action in that the metabolic products of the parent alcohols do not contribute to the toxic 26 
endpoint evaluated. In this case study, the chemical category is limited to the readily bioavailable 27 
(C5 to C13) analogues. The toxicokinetic premise includes rapid absorption via the 28 
gastrointestinal tract, distribution in the circulatory system, and first-pass metabolism in the liver 29 
resulting in metabolism via oxidation to CO2 and with minor elimination of oxidative 30 
intermediate as glucuronides. Two analogues have experimental 90-day oral repeated-dose 31 
toxicity data which exhibit qualitative and quantitative consistency. Typical findings include 32 
decreased body weight, slightly increased liver weight which, in some cases, is accompanied by 33 
clinical chemical and haematological changes but generally without concurrent histopathological 34 
effects at the Lowest Observed Effect Level (LOEL). Chemical similarity between the analogues 35 
is readily defined by a variety of structure-related properties; data uncertainty associated with 36 
toxicokinetic and toxicodynamic similarities is low. Uncertainty associated with mechanistic 37 
relevance and completeness of the read-across is reduced by the concordance of in vivo and in 38 
vitro results, as well as high throughput and in silico methods data. As shown in detail, the 90-39 
day oral repeated-dose toxicity No Observed Effect Level (NOEL) value of 1000 mg/kg bw/d for 40 
1-pentanol and 1-hexanol based on LOEL of very low systemic toxicity can be read across to fill 41 
the data gaps of the untested analogues in this category with acceptable uncertainty.  42 
Keywords: read-across, n-alkanols, repeated-dose toxicity, No Observed Effect Level (NOEL), 43 
Lowest Observed Effect Level (LOEL), weight-of-evidence (WoE), uncertainty 44 
  45 
1 Introduction 46 
1.1 Read-across 47 
The principal philosophy of a toxicological read-across is chemicals that are similar in molecular 48 
structure will exhibit similar chemical properties, and as such, they will exhibit similar 49 
toxicokinetic and toxicodynamic properties. Thus, experimentally-derived toxicokinetic and 50 
toxicodynamic information and data from one chemical, the source substance, can be read across 51 
to fill the data gap for a second chemical, the target substance which is similar. This type of data 52 
gap filling is particularly useful for cosmetic ingredients where in vivo testing in Europe is 53 
prohibited by legislation [1]. 54 
As a predictive tool, read-across has been used by industry and regulators for decades [2]. With 55 
advances in non-animal test methods, read-across today is held to a different standard than at the 56 
turn of the century. Specifically, there is greater expectation in terms of the identifying 57 
similarities and addressing uncertainties within the read-across argument [3].  58 
In order to facilitate the development of better practical guidance on how to formulate high 59 
quality read-across justifications, a series of case studies have been conducted by the authors. 60 
This case study illustrates specific considerations where metabolism of all the analogues in the 61 
chemical category is highly similar and plays no role in determining toxicological similarity [4]. 62 
The case study is also intended to illustrate how non-animal data, in the form of high throughput 63 
screening (HTS) data and in silico molecular screening, may be used to reduce uncertainties, as 64 
well as, add to mechanistic plausibility and weights-of-evidence (WoE) to any read-across 65 
argument. 66 
While it is easy to establish similarity based on structure and chemical properties, this similarity 67 
alone is often not enough to accept a toxicological read-across prediction for sub-chronic and 68 
chronic health endpoints. To justify the applicability domain of the category it is often necessary 69 
to establish toxicodynamic, and to a greater extent toxicokinetic, similarity within the category. 70 
The purpose of this research was to demonstrate the how read-across predictions of the repeated-71 
dose toxicity no observed effect level (NOEL) value based on a consistent set of lowest observed 72 
effect level (LOEL) symptoms could be performed and substantiated for a category of n-alkanol 73 
analogues. Specifically, the category based data providing information to reduce uncertainties, 74 
and add to the WoE associated with read-across predictions of specified in vivo data. Thus, the 75 
estimations from the read-across are quantitative and with sufficiently low uncertainty that they 76 
may be used in risk assessments. As such, the predicted 90-day repeated-dose NOEL values are 77 
accompanied by sufficient relevant in vivo and non-animal test data to make the uncertainties 78 
equal to what would be expected from running a test using a protocol similar to Organization for 79 
Economic Co-Operation and Development (OECD) TG 408. In the present study, a previously 80 
reported ‘strategy’ was employed to assess similarities and overall completeness of the read-81 
across [5].  82 
1.2 C5 – C13 n-alkanols: overview of existing knowledge 83 
Historically, intermediate chain-length n-alkanols are considered nonpolar narcotics which act 84 
mechanistically in a manner similar to depressant anaesthetics. Fang, McKim, Koleva and their 85 
co-workers [6-8] reported multiple-regression type quantitative structure-toxicity relationships 86 
(QSARs) for oral log LD50-1 data for rodents and the 1-octanol/water partition coefficient (log 87 
Kow). Comparison of measured toxicity data with predictions from baseline QSARs reveals that 88 
saturated monohydric alcohols consistently behave as classic nonpolar narcotics [9]. 89 
The efficacy of n-alkanols to induce ataxia [10] and enzyme release from liver cells [11] has 90 
been interpreted as being due to the hydrophobic property of the alkanols. Perfused rat liver 91 
toxicity data from Strubelt et al. [12] for 1-pentanol (exposure 65.1 mmol/l for 2 hours) are 92 
reported in Table 1. These data support the premise that mammalian ex vivo toxicity (e.g., O2 93 
consumption and ATP production) of n-alkanols is due to membrane partitioning resulting in 94 
loss of membrane integrity (i.e., cytosolic enzyme leakage (LDH) but not glutathione (GSH) 95 
binding). 96 
Table 1. In vitro toxicity profiles for 1-pentanol. 97 
LDH – lactate dehydrogenase; ATP - adenosine triphosphate; GSH – reduced glutathione 98 
 99 
Due to bioavailability, and distribution and mechanistic considerations, the applicability domain 100 
for this case study is limited to n-alkanols with a carbon atom (C) chain length range of C5 to 101 
C13. For example, since longer-chain derivatives are typically transported via carrier molecules, 102 
they are not included in this chemical category. Also, shorter-chain derivatives are not included 103 
in this chemical category, as they have the potential to volatilise. 104 
The general anaesthetic potency of several members of this homologous series of saturated 105 
aliphatic alcohols was determined in tadpoles, using the loss of righting reflex as the criterion of 106 
anaesthesia [13]. In this series, anaesthetic potency increased with chain length and was maximal 107 
for 1-dodecanol. The cut-off in potency was between C12 and C14, such that 1-tridecanol was a 108 
partial anaesthetic. 109 
n-Alkanols within the range C5-C13 are expected to be readily absorbed by the gastrointestinal 110 
tract and distributed in the blood in solution. n-Alkanols are metabolised mainly in the liver via 111 
Name log Kow   O2 consumption 
(mol/g x min) 
ATP 
(mol/g) 
LDH 
(U/l) 
GSH 
(mol/g) 
Control  1.54 ± 0.07 1.25 ± 0.20   1109 ± 265 2.52 ± 0.29 
1-Pentanol 1.40 0.06 ± 0.01 0.20 ± 0.03 28959 ± 4142 2.82 ± 0.36 
alcohol dehydrogenase to corresponding aldehydes and, subsequently, by aldehyde 112 
dehydrogenase to the corresponding carboxylic acids [14]. The fatty acid derivatives of 113 
intermediate size n-alkanols are readily taken up by mitochondria, where they are degraded by β-114 
oxidation, especially in hepatocytes and myocytes [14]. However, generally <10% of the dose of 115 
these primary alcohols form glucuronic acid conjugates which are excreted in the urine [15]. 116 
Voskoboinikova [16] and Opdyke [17] have summarised the historical literature on aliphatic 117 
alcohol toxicity. More recently, the toxicity of alkanols containing from one to six C-atoms has 118 
been reviewed [18]. A cursory summary of the rat oral acute and oral repeated-dose toxicity of 119 
intermediate size n-alkanol are presented in Table 2. In general, n-alkanols acute oral toxicity 120 
(i.e., LC50) is very low, ranging from 1500 to 5000 mg/kg bw with an average value of 3000 121 
mg/kg bw. n-Alkanols are only slightly toxic in oral repeated-dose testing; typically, the rodent, 122 
oral, 90-day, repeated-dose NOEL in mg/kg bw/d is in the range of 1/2 - 1/3 the LC50 value. 123 
This value is characteristically based on clinical symptoms, haematological values outside the 124 
normal range, or whole body effects different from normal. However, if ingested in large enough 125 
quantities (i.e., near lethal doses), n-alkanols have the potential to cause systemic damage to the 126 
liver, heart, kidneys, and/or nervous system (see citations in Table 2 for details). 127 
Table 2. Rat oral acute and repeated-dose toxicity of selected n-alkanols. 128 
Alcohol 
Oral LD50 
(mg/kg) 
Reference 
90-d Oral NOAEL 
(mg/kg bw/d)  
Reference 
1-Pentanol 2200 [19] 1000 [20] 
 3645 [21] 1000 [21] 
1-Hexanol 4590 [22] 1127 M [23] 
 4870 [24] 1243 F [23] 
1-Heptanol 3250 [24] > 1000 [26] 
 6200 M [25, 26]   
 5500 F [25, 26]    
1-Octanol >5000 [27] Not determined  
Nonyl alcohol (assumed 
1-nonanol) 
3560 [17] Not determined  
1-Decanol 4720 [28] Not determined  
Undecyl alcohol 
(assumed 1-undecanol) 
3000 [29] 2000a [30] 
Lauryl alcohol (assumed 
1-dodecanol) 
> 2000 [31] 2000 [31, 32] 
1-Tridecanol 17200 [33] Not determined  
a NOAEL value is recorded as experimental result, but the details in the report indicate that it is read across from 1-dodecanol 129 
(CAS 112-53-8). 130 
M- male, F- female 131 
 132 
2. Method and Materials 133 
This evaluation of selected n-alkanols follows the workflow of Przybylak et al. [5]. It is in accord 134 
with the guidelines proposed by OECD [34] and Schultz and co-workers [35]. In vivo data used 135 
in the assessment were taken from the literature, including ECHA REACH Registered 136 
Substances database [36]. Mechanistic relevance, as well as toxicokinetic and toxicodynamic 137 
similarity of the category analogues was established using relevant non-animal data. 138 
2.1 Target and Source Substances 139 
In this case study, the analogues (listed in Table 3) include seven target and two source 140 
chemicals; the latter, those with repeated-dose data derived from a 90-day OECD TG 408 assay, 141 
are noted in bold print. This list is inclusive, as defined by the limitations of the applicability 142 
domain. The analogues represents n-alkanols which are found in governmental or industrial 143 
inventories (e.g., OECD High Production Volume Chemicals). Additional substance identifier 144 
information, such as chemical structures and molecular formulas, are available in Table 1 of the 145 
supplemental information. 146 
Table 3. n-Alkanols considered as part of the chemical category for read-across. Compounds in 147 
bold indicate the source substances. 148 
ID Name CAS No. SMILES 
1 1-Pentanol 71-41-0 CCCCCO 
2 1-Hexanol 111-27-3 CCCCCCO 
3 1-Heptanol 111-70-6 CCCCCCCO 
4 1-Octanol 111-87-5 CCCCCCCCO 
5 1-Nonanol 143-08-8 CCCCCCCCCO 
6 1-Decanol 112-30-1 CCCCCCCCCCO 
,  1-Undecanol 112-42-5 CCCCCCCCCCCO 
8 1-Dodecanol 112-53-8 CCCCCCCCCCCCO 
9 1-Tridecanol 112-70-9 CCCCCCCCCCCCCO 
 149 
2.2 Endpoint 150 
The NOEL for the 90-day rat oral repeated-dose is the single endpoint for which this category 151 
approach is applied. The 90-day oral repeated-dose data for 1-pentanol and 1-hexanol are 152 
particularly well-suited for read-across; the NOELs are based on experimental results from a 4-153 
dose exposure scenario (0, <100, between 100 and 500, and ≥ 1000 mg/kg bw/d) following a 154 
standard test guideline (OECD TG 408) where the LOEL symptoms are reported. Moreover, 155 
there are supporting repeated-dose results for 1-heptanol, 1-undecanol and 1-dodecanol from 156 
OECD TG 422 studies, with the exposure durations for males being 28 days and for females 54 157 
days. 158 
2.3 Hypothesis of the category 159 
The premise for this read-across case study is: 160 
 n-Alkanols of intermediate chain length (i.e., C5 to C13) are direct acting toxicants (i.e., 161 
metabolic activation and detoxification is not a factor in toxicity) with a similar reversible 162 
mode of action (i.e., non-polar narcosis or simple anaesthesia). 163 
 Within C5 to C13 derivatives, C-atom chain length affects most physico-chemical 164 
properties (e.g., Log Kow values increase with increasing chain length). However, this 165 
trend, while toxicologically relevant in fish toxicity and in vitro assays, is not observed in 166 
mammalian acute and sub-chronic toxicity via oral exposure. 167 
 These primary alkanols are rapidly and nearly completely absorbed from the gut and 168 
distributed in the blood in solution; first pass metabolism leads to two-step oxidative 169 
metabolism in the liver resulting in corresponding carboxylic acid, which subsequently 170 
undergoes mitochondrial β-oxidation to CO2 with minor amounts of glucuronidation with 171 
subsequent elimination of the phase II metabolite in the urine. 172 
 Toxicodynamically, these primary alkanols are highly similar. Briefly, in vivo they 173 
exhibit very low systemic toxicity; in vitro and in silico they exhibit no chemical 174 
reactivity or receptor-mediated interactions. 175 
 90-day oral rat repeated-dose NOAEL data for 1-pentanol and 1-hexanol can be read 176 
across to other category members listed in Table 3 with acceptable uncertainty. 177 
3 Results 178 
3.1 Read-across justification 179 
In order to conduct a read-across, there is the requirement for high quality in vivo data for the 180 
endpoint under consideration [5, 34, 35]. In this case, is 90-day oral repeated dose-toxicity for 181 
rats in the form of a NOEL value and LOEL symptoms from a study similar to OECD TG 408. 182 
From a repeated-dose perspective, test results of n-alkanols are extensive. 1-Pentanol was orally 183 
administered to rats following OECD TG 408 at dose levels of 0, 50, 150 or 1000 mg/kg bw/d 184 
for 13 weeks [20, 21]. The “no-outward-effect level” (assumed to be the NOEL) was 1000 185 
mg/kg/day. 186 
In a non-standard rat oral repeated-dose assay similar to an OECD TG 408 assay, animals were 187 
exposed to 0.25% (based on nominal concentrations in the diet) and 0.50% for 13 weeks; 1.0% 188 
for 10 weeks, then 2.0% (week 11), 4.0% (week 12) and 6.0% 13 weeks of 1-hexanol [23]. The 189 
NOAEL for 1-hexanol was determined to be 1100 mg/kg bw/d (1127 mg/kg bw/d for male and 190 
1243 mg/kg bw/d for female rats). 191 
While the endpoint read across in this exercise is the 90-day oral repeated-dose NOEL, there is 192 
also high quality repeated-dose toxicity NOEL/LOEL data for shorter duration studies (e.g., 193 
OECD TG 422). Since these data are both qualitatively and quantitatively similar to the 90-day 194 
data, they may be used as WoE and to confirm that all category members are within the endpoint 195 
domain. 196 
1-Heptanol was administered orally to rats under OECD TG 422 and 0, 100, 300 and 1000 197 
mg/kg bw/d [26]. No treatment related changes were noted for all parameters (e.g., biochemical, 198 
haematological and clinical parameters, as well as body weight, food consumption and 199 
neurobehavioral effects). 200 
Following OECD TG 422, oral repeated-dose toxicity of 1-undecanol in rats was evaluated at 201 
doses of  0, 100, 500, 2000 mg/kg bw/d [30]. A NOEL for systemic toxicity of 2000 mg/kg 202 
bw/d was determined in male rats, in the absence of toxicologically significant effects at any 203 
dose level. 204 
Following OECD TG 422, rats were exposed to 1-dodecanol in the diet in concentrations of  0, 205 
100, 500 and 2000 mg/kg/ bw/d [31]. A NOEL for systemic toxicity of 2000 mg/kg bw/d was 206 
determined in male rats, in the absence of toxicologically significant effects at any dose level. 207 
In summary, while protocols vary, results for repeated-dose toxicity test results exhibit 208 
qualitative and quantitative consistency. Phenotypic results from repeated exposure to n-alkanols 209 
reflect mild changes consistent with low-grade effects and include decreased body weight, 210 
accompanied by clinical chemical and haematological changes, but generally without concurrent 211 
histopathological effects. 212 
3.2 Applicability domain 213 
As previously noted, the applicability domain for this case study is confined to straight-chain 214 
primary alkanols of intermediate size, C5 to C13. 215 
3.3 Purity/impurities 216 
Read-across is based on the structural similarity of the main constituents of the source and target 217 
substances. Toxicity may actually be determined by an impurity, therefore it is important to 218 
provide a purity/impurity profile for all analogues. However, in this case it was not possible to 219 
take into account impurities based on production. Since the category is structurally limited, the 220 
impurities are expected to be similar if not the same across the members and are not expected to 221 
significantly impact the toxicity profile of any analogue. However, it is acknowledged for 222 
regulatory decisions such information may be required. 223 
3.4 Data matrices for assessing similarity 224 
In order for a read-across prediction to be accepted, there is the requirement to establish 225 
similarity between the source and target substance [5, 34, 35]. While structural similarity is a 226 
minimum, toxicokinetic similarity, especially for metabolism, and toxicodynamic similarity, 227 
especially in regard to mechanistic plausibility, is required for sub-chronic endpoints such as 90-228 
day oral repeated dose-toxicity [5]. 229 
3.4.1 Structural similarity 230 
As demonstrated in Tables 1 and 3 of the supplemental information, all the n-alkanols included 231 
in the category are structurally highly similar. Specifically, they: 1) belong to a common 232 
chemical class, aliphatic alcohols and subclass, n-alkanols, and 2) possess common molecular 233 
scaffolding, a C-atom backbone with a straight-chain configuration. Structurally, the only 234 
variable is the length of the hydrocarbon backbone, C5-C13. 235 
3.4.2 Chemical property similarity 236 
As demonstrated in Table 2 of the supplemental information, all the n-alkanols included in the 237 
category have many of their physico-chemical properties determined experimentally. Thus, when 238 
required calculated values, which are based on these measured values can be accepted with high 239 
confidence. Properties, with the exception of density and pKa, trend in value related to C-atom 240 
number within the scaffold. Specifically, all category members exhibit molecular weights from 241 
88 to 200 g/mol. Hydrophobicity (as modelled by log Kow) increases with number of C-atoms 242 
from >1.0 to <6.0, vapour pressure and water solubility decrease with molecular size, melting 243 
point and boiling point increase with molecular size, and density is constant at 0.8±0.1g/cm3. 244 
Since there is no readily ionisable substituent the pKa is consistent at ≈ 15.2. 245 
3.4.3 Chemical constituent similarity 246 
As shown in Table 3 of the supplemental information, all the n-alkanols included in the category 247 
have common constituents in the form of: 1) a single key substituent, -OH, and 2) structural 248 
fragments, -CH3 and -CH2-. 249 
3.4.4 Toxicokinetic similarity 250 
Limiting the range of C-atoms for the applicability domain reduced the impact of size on 251 
adsorption, distribution, metabolism and elimination (ADME). From a bioavailability standpoint, 252 
the analogues exhibit in in silico models linear trend with molecular weight. Such modelling 253 
reflects hydrophobic-dependent uptake. 254 
The toxicokinetic understanding of alkanols is reasonably complete despite the fact that the 255 
experimental data, as summarised in Table 4 of the supplemental information, are limited. 256 
Absorption, distribution and elimination are not considered factors in these predictions. For 257 
example, 1-octanol is rapidly absorbed after oral administration (i.e., bioavailability >80%). 1-258 
Octanol is excreted mainly as CO2, and to a lesser extent as n-octyl glucuronide [17, 27, 37]. 259 
Other n-alkanols exhibit similar toxicokinetics, with n-alcohols generally forming <10% of the 260 
dose as glucuronic acid conjugates and are excreted in the urine [15]. 261 
It is generally accepted that, regardless of species, metabolism of n-alkanols is highly efficient 262 
and proceeds in a similar fashion [38]. Basically, there only degradative or detoxification 263 
pathways involved in the metabolism of n-alkanols. It is universality accepted that in the first 264 
step of the biotransformation, the alcohols undergo stepwise intracellular oxidation to the 265 
corresponding carboxylic acids, followed by a stepwise C2 unit elimination via mitochondrial β-266 
oxidation [38].  267 
3.4.5 Metabolic similarity 268 
As demonstrated in Table 5 of the supplemental information, all of the category members 269 
undergo oxidation and hydroxylation in metabolic simulations. Briefly, mammalian catabolism 270 
of fatty acids, which most often takes place in the mitochondria, leads to the formation of acetyl- 271 
coenzyme A (CoA), enters the TCA cycle and reduces nicotinamide adenine dinucleotide 272 
(NADH) and flavin adenine nucleotide (FADH2) which are used by the electron transport chain 273 
to produce ATP [14]. 274 
 While other processes, including ω-oxidation and α-oxidation, are known to take place, β-275 
oxidation is the most common catabolic process in n-alkanol metabolism. It is highly likely that 276 
the n-alkanols included in the category will be nearly completely metabolised (i.e., >90%) via 277 
the tricarboxcylic acid (TCA) cycle. It is generally agreed that cytosolic fatty acids are activated 278 
for degradation by conjugation with CoA. β-Oxidation of saturated fatty acids consists of a 279 
recurring cycle of four reactions [14]. In acids with an even number of C-atoms, this cycling 280 
continues until two molecules of Acetyl-CoA are produced in the final reaction. Acetyl-CoA is 281 
available to be further metabolised in the TCA cycle. In acids with an odd number of C-atoms, 282 
the end product is propionyl-CoA, which must be converted to succinyl-CoA to enter the TCA 283 
cycle. 284 
3.4.6 Toxicophore similarity 285 
The severe limitation of the structural domains sharply reduces the likelihood of differences in 286 
toxicophores between the target and source analogues. As demonstrated in Table 6 of the 287 
supplemental information, none of the n-alkanols included in the category are associated with 288 
any toxicophore based on in silico profilers within the OECD QSAR Toolbox V3.4. 289 
3.4.7 Mechanistic plausibility similarity 290 
While there is no mammalian adverse outcome pathway for the hypothesized mode of action, it 291 
is generally accepted that the acute toxicity of intermediate chain n-alcohols is the result of 292 
narcosis [5-9]. There are both theoretical and biochemical evidence for the cell membrane being 293 
the site of action for anaesthetic-like chemicals [10-11]. Narcosis, in the broadest sense, is the 294 
reversible, non-covalent disruption of hydrophobic interactions within membranes with a 295 
particular volume fraction, rather than molar fraction [39]. It is the accumulation of alcohols in 296 
cell membranes which disturbs their function; however, the exact mechanism is not yet known. 297 
There are three competing theories of general anaesthetic action: 1) the lipid solubility-298 
anaesthetic potency correlation (i.e., the Meyer-Overton correlation), 2) the modern lipid 299 
hypothesis, and 3) the membrane protein hypothesis [c.f., 40-41]. 300 
As stated in Table 7 of the supplemental information, the n-alkanols included in the category are 301 
associated with the simple narcosis mechanism of toxicity that is equivalent to depressant 302 
anaesthetics [6].  Additivity of primary alkanols in joint effect studies was demonstrated in 303 
injection anaesthesia studies in rats [6],. This observation of additivity is consistent with the 304 
premise that n-alkanols exhibit a common mechanism of action. More importantly, Fang et al. 305 
[6] demonstrated additivity or slight deviations from additivity for alkanols with the conventional 306 
inhaled anaesthetic desflurane (1,2,2,2-tetrafluoroethyl difluoromethyl ether). The latter support 307 
the contention that the mechanisms of action of n-alkanols is depressant anaesthesia. 308 
The effect of various primary alkanols on the CNS was studied by using rat brain synaptosomal 309 
membranes as an in vitro model [41]. The activity of (Ca2+/Mg2+) ATPase and the membrane 310 
fluidity were determined. Specifically, the n-alkanols exhibited an increased molar inhibition of 311 
the ATPase activity, with an increase in the carbon chain length up to 1-octanol. 1-Octanol and 312 
1-decanol caused a biphasic effect on the ATPase activity, depending on the n-alkanol 313 
concentration, whereas 1-dodecanol caused a stimulation of the ATPase activity. All alkanols 314 
studied caused an increased fluidity of the membrane; however, changes in the membrane 315 
fluidity do not seem to be a pre-requisite of the ATPase inhibition [41]. 316 
The Fish Acute Toxicity Syndrome (FATS) approach put forth by McKim et al. [7] has furthered 317 
our mechanistic understanding and the effects of intermediate chain saturated alcohols in fish 318 
more than anything else. The FATS approach is based on physiological response sets from 319 
spinally transected rainbow trout (Oncorhynchus mykiss) exposed to model chemicals. Briefly, in 320 
vivo biochemical and respiratory-cardiovascular responses were measured during lethal aqueous 321 
exposures; the responses and their interdependence formed a complex data matrix, with the best 322 
response variables for mechanisms of action being determined with multivariate statistics. The 323 
FATS for 1-octanol is characterised by a striking slow-down in all respiratory and cardiovascular 324 
functions [7] that makes it distinct from other modes of actions. The action of 1-octanol is 325 
consistent with depressant anaesthesia. 326 
The contributions of functional groups in acute rat oral toxicity have been calculated using 327 
alkanes as the baseline [40]. The toxic contribution of the OH group is -0.108. This situation 328 
(negative contribution to toxicity as compared to corresponding alkane) has not been observed in 329 
acute fish toxicity because the threshold of excess toxicity is too high to distinguish differences 330 
in toxicity. Critical body residues (CBRs) calculated from percentage of absorption and 331 
bioconcentration factors indicate that most of aliphatic alcohols share the same modes of toxic 332 
action between fish and rat. Specifically, fish and rat log (1/CBR) and number of alcohols are 333 
1.65; 18 and 1.58; 348, respectively [40]. 334 
In summary, there are several lines of evidence that support the contention that all the analogues 335 
within the domain act in a similar fashion and that fashion is not different from simple 336 
anaesthesia or non-polar narcosis.   337 
3.4.8 Other in vivo endpoint similarity 338 
In mammals, alkanols are considered baseline inhalation toxicants which model as simple 339 
narcotics [9]. Based on acute oral toxicity, n-alkanols belong to Category 4 which do not require 340 
a hazard label for acute oral toxicity. Their LD50 values are very low, typically ranging from 341 
1000 to >5000 mg/kg bw with an average value of 3000 mg/kg bw (see Table 2). In mammals, 342 
mild to moderate sub-lethal toxicity from a single oral dose of intermediate size alkanols include 343 
general gastrointestinal symptoms (e.g., nausea, vomiting, abdominal cramps and diarrhoea) 344 
associated with irritation. High ingested doses (i.e., near acute lethal levels) can cause 345 
gastrointestinal haemorrhage and liver injury. For example, in the rat, the LD50 for 1-octanol is 346 
>5000 mg/kg [17]; the only symptoms of intoxication observed were moderately to severely 347 
ruffled fur and mild sedation. The symptoms had disappeared completely 24 hours later. The 348 
growth of the exposed animals was similar to that of the controls. 349 
In fish, alkanols are considered to act via the nonpolar narcosis mode of action [42, 43]. Within 350 
the USEPA DSSTox Fathead Minnow Acute Toxicity (EPAFHM) database, alkanols are 351 
represented. They exhibit toxic potencies not statistically different from baseline predictions. 352 
Because of concerns for aquatic toxicity, a large number of alcohols, especially saturated ones, 353 
have been tested in vitro for cell population growth inhibition [44]. Structure-activity results 354 
from in vivo and in vitro tests are highly consistent [45]. Briefly, from a structural standpoint, the 355 
aquatic toxicity of alkanols is partition-dependent, regardless of endpoint being assessed. 356 
Generally, for alkanol exposures in in vitro assays, results are attributed to unspecific 357 
interactions with biological membranes [11]; such effects are typically directly correlated with 1-358 
octanol/water partition coefficients (c.f. [46]). 359 
3.4.9 Relevant in vitro and in silico data 360 
In an effort to further support the mechanistic argument for this read-across information form 361 
two new methods were examined. Specifically, relevant HTS data in the form of ToxCast data 362 
[47, 48] and of in silico nuclear receptor binding predictions [49] were evaluated. Within the 363 
USEPA toxicity forecaster program (ToxCast) [50], data are available for the majority of the n-364 
alkanol derivatives (see Table 8 of the supplemental information). Of the 711 possible assays 365 
that form the ToxCast scheme, 1-octanol, 1-undecanol, 1-dodecanol and 1-tridecanol have been 366 
evaluated in 602 of them. Additionally, 1-hexanol, 1-heptanol and 1-decanol have been assessed 367 
in about 250 assays. Lastly, 1-nonanol has been tested in 150 ToxCast assays. The number of 368 
active assays varies from none for 1-octanol to 25 for 1-undecanol and 30 for 1-tridecanol. 369 
Within ToxCast, the n-alkanols are among the “least promiscuous chemical classes”; < 2.74% of 370 
the ToxCast assays showing any activity up to highest concentration tested and none of the 371 
active assay are associated with specific bioactivity. 372 
Only four non-specific cell viability qHTS assays within the Toxcast suite were positive for four 373 
of the tested n-alkanol analogues; no assay exhibits activity for five or more of the category 374 
analogues. Specifically,  the Tox21_ELG1_LUC_Agonist_viability, 375 
Tox21_TR_LUC_GH3_Antagonist_viability, Tox21_AhR_viability and 376 
Tox21_Aromatase_Inhibition_viability show a positive response with four n-alkanols but there is 377 
no consistency among which analogues are positive. 378 
Alkanols were screened with a variety of in silico profilers [49]. Specifically, profilers for 379 
nuclear receptor binding were run to identify potential binding to the following nuclear 380 
receptors; PPARs (peroxisome proliferator-activated receptors), AR (androgen receptor), AHR 381 
(aryl hydrocarbon receptor), ER (oestrogen receptor), GR (glucocorticoid receptor), PR 382 
(progesterone receptor), FXR (farnesoid X receptor), LXR (liver X receptor), PXR (pregnane X 383 
receptor), THR (thyroid hormone receptor), VDR (vitamin D receptor), as well as RAR/RXR 384 
(retinoic acid receptor/ retinoid X receptor). The evaluation of potential binding to the receptors 385 
is based on structural fragments and physico-chemical features that have been identified as 386 
essential to bind to these nuclear receptors and induce a response. As noted in Table 6 of the 387 
supplemental information, no potential receptor binding was predicted. It is worth noting that 388 
ToxCast also tested for all of these receptors, and all corresponding assays were negative. 389 
Taken collectively, the HTS and in silico findings are not inconsistent with the cited in vivo data. 390 
The premise that, oral repeated-dose toxicity of n-alkanols are considered to be nonpolar 391 
narcotics and act in a manner similar to depressant anesthetics is consistent with the ToxCast 392 
data and receptor binding simulations results which indicate no activity associated with a specific 393 
mode of action. 394 
 395 
4. Statement of uncertainty 396 
The categorical assessments of uncertainties along with summary comments are presented in 397 
Tables 4 and 5. Briefly, chemical similarity is limited by chain length but has no impact on 398 
repeated-dose toxicity. Data uncertainty with the fundamental aspects of toxicokinetics is low. 399 
Regardless of the species of mammals, all such category members are judged to be readily 400 
absorbed orally and to have similar distributions; metabolised via oxidation to the acid 401 
derivative, subsequently degraded to CO2 via mitochondrial oxidation, and/or eliminated as a 402 
glucuronide. Data uncertainty with the fundamental aspects of toxicodynamics is low, in that 403 
category members exhibit a very low-toxic profile with respect to in vivo effects (i.e., NOEL and 404 
LOEL), as well as with respect to in vitro and new-methods effects. n-Alkanols are 405 
experimentally associated with the nonpolar narcosis mechanisms of toxicity. The simple 406 
narcosis (i.e., reversible anaesthesia) mode of toxic action is driven by partitioning into the 407 
biophase. While well-studied, this molecular mechanism is not well-understood and no adverse 408 
outcome pathway (AOP) is currently available. Moreover, it is unclear if oral repeated-dose 409 
toxicity is related to this mechanism; however, there is no evidence to suggest it is not. 410 
Uncertainty associated with mechanistic relevance and completeness of the read-across (i.e., 411 
uncertainty in the predictions) while initially low-to-moderate is reduced to low with the addition 412 
of ToxCast and in silico screening data. The major source of uncertainty for this group of 413 
alcohols is associated with what is essentially a “low-toxic” prediction. 414 
Table 4. Assessment of data uncertainty and strength-of-evidence associated with the 415 
fundamentals of chemical, transformation/toxicokinetic and toxicodynamic similarity. 416 
 417 
Similarity 
Parameter 
Data 
Uncertaintya 
Strength-of-
Evidenceb 
Comment 
Substance 
identification, 
structure and 
chemical 
classifications 
low high All category members are discrete organic substance 
of simple structure. They all have CAS numbers, 
similar 2D structure and belong to the same chemical 
class (primary aliphatic alcohols) and same subclass 
(straight-chain alcohols). 
Physio-chem & 
molecular 
properties 
Empirical: 
low 
 
Modelled: 
low 
high All category members are appropriately similar with 
respect to key physico-chemical and molecular 
properties. Where appropriate (e.g., log Kow) 
changes in values are linked to changes in C-atom 
chain length. There is a high degree of consistency 
between measured and model estimated values. 
Substituents, 
functional groups, 
& extended 
structural 
fragments 
low high Substituents and functional groups are consistent 
across all category members. There are no extended 
structural fragments. 
Transformation/tox
icokinetics and 
Empirical:  
in vivo: low 
medium While in vivo absorption data are reported for only 
one category member, there is evidence for similar 
Similarity 
Parameter 
Data 
Uncertaintya 
Strength-of-
Evidenceb 
Comment 
metabolic 
similarity 
in vitro: none 
 
Simulated: 
low 
toxicokinetics and metabolic pathways. Comparison 
of results from empirical studies and model 
predictions indicate similar metabolism among 
category members. It is universally accepted that n-
alkanols are typically degraded to CO2. Absorption 
and distribution are not considered factors in these 
predictions. 
Potential metabolic 
products 
Simulated: 
  low 
high Based on in silico metabolic simulations, metabolites 
from oxidation and hydroxylation are predicted to be 
produced by all the category members. 
Toxicophores 
/mechanistic alerts 
medium high Based on in silico profilers, no category member 
contains any established toxicophores. 
Mechanistic 
plausibility and 
AOP-related events 
medium high Although no AOP is currently available for the 
hypothesized mode of action, many category 
members have been tested for what is generally 
accepted as mechanistically-relevant events (i.e., 
anaesthesia and narcosis). 
Other relevant, in 
vivo, in vitro and ex 
vivo endpoints 
low high Although not directly related to the repeated-dose 
endpoint, many category members have been tested 
for in vivo acute effects in rodents and fish. In 
addition, many category members have been tested in 
vitro for cellular effects. There is general agreement 
in the trend of the reported EC50 values. The primary 
alkanols are among the “least promiscuous chemical 
classes” within ToxCast with no positive assay being 
associated with specific bioactivity. Primary alkanols 
reveal no propensity for nuclear receptor binding 
within the COSMOS suite of in silico profilers. 
a Uncertainty associated with underlying information/data used in the exercise (empirical, modelled; low, medium, 418 
high) 419 
b Consistency within the information/data used to support the similarity rational and prediction (low, medium, high)  420 
 421 
 422 
Table 5. Assessment of uncertainty associated with mechanistic relevance and completeness of 423 
the read-across. 424 
Factor Mechanistic 
Uncertaintya 
Comment 
The problem and 
premise of the 
read-across 
Low The endpoint to be read across, oral 90-day repeated-dose 
toxicity, for n-alkanols is well-studied and fairly well-understood 
mechanistically. The scenario of the read-across hinges on 
metabolism not affecting toxicity and the mode of toxic action 
being reversible narcosis. Thus, n-alkanols have no obvious 
chemical reactivity, do not bind to any known receptor and 
exhibit no specific mode of toxic action. 
In vivo data read-across 
Number of 
analogues in the 
source set 
Low; 5of 9 
analogues 
While there are five tested category members, two 1-pentanol and 
1-hexanol, have high quality in vivo 90-day, oral repeated-dose 
data usable for read-across. 
Quality of the in 
vivo apical 
Low; consistent 
lowest observed 
Generally, the in vivo data are consistent with regard to 
qualitative description of repeated-dose effects. LOEL affects are 
typically haematological or whole body parameters and not 
endpoint data read 
across 
effect concentration 
(LOEC) symptoms 
organ-specific effects. The high quality empirical data (e.g., 
OECD TG 408) for the 90-day repeated-dose endpoint exists for 
1-pentanol and 1-hexanol are supported by lower quality (i.e., 
OECD TG 422) oral repeated-dose toxicity data for 1-heptanol, 1-
unidecanol and 1-dodecanol.  
Severity of the 
apical in vivo 
hazard 
Low; strong 
evidence that the 
90-day NOAEL 
value is 1/20 to 
1/10 of the LD50 
values.  
The consensus is that n-alkanols have no obvious chemical 
reactivity, do not bind to any known receptor and exhibit no 
specific mode of toxic action. Potency data for the in vivo 90-d 
oral repeated-dose NOAEL are 1000 mg/kg bw/d based on 
general whole body effects for both sexes. 
Evidence to the biological argument for read-across 
Robustness of 
analogue data set 
Low; numerous 
endpoints reveal the 
same structure-
activity 
relationships. 
The available data from acute in vivo and in vitro studies for the 
category members are extensive with several assays being used to 
assess most if not all the analogues, especially the source 
analogues. The tests were judged to be reliable and conducted 
under the appropriate conditions. 
Concordance with 
regard to the 
intermediate and 
apical effects and 
potency data 
Low to medium; 
limited by indirect 
rationale (e.g., acute 
to chronic) of 
mechanistic 
plausibility. 
Since there is no toxicity pathway for repeated-dose effects for 
this chemical category, there are no true intermediate events. 
However, there is concordance between anaesthesia and slow-
down in all respiratory and cardiovascular functions. There is 
agreement among the dose-response relationships of the tested 
category members for other relevant endpoints.  
Weight-of-
Evidence 
High; experimental 
and predicted 
information among 
and between the 
category member is 
consistent with 
stated premise 
Overall the available information is generally consistent with the 
stated premise.  The structural limitations (i.e., n-alkanols) on the 
category strengthen the weight-of –evidence (WoE). While the 
toxicokinetics data are limited, the consistency in metabolism and 
simplicity of the metabolic pathway adds to the WoE. The fact the 
source substances in vivo data is supported by similar data for 
other analogues adds to the WoE. The fact that there is consistent 
relevant in vitro data for most category members strengthens the 
WoE. The consistency in results as related to simple membrane 
partitioning strengthens the WoE. The consistent negative results 
with ToxCast assays and screening with in silico receptor-binding 
profilers add to the WoE. 
a Uncertainty: low, medium, high 425 
5. Statement of the conclusions 426 
This is the second in a series of read-across case studies; this particular study examines a 427 
category of similar compounds that do not require (or do not undergo) metabolism to exert a 428 
potential adverse human health effect [51]. In vivo oral repeated-dose exposure to n-alkanols 429 
gives rise to a set of nonspecific symptoms, including clinical symptoms, haematological values 430 
outside the normal range, or whole body effects different from normal. Limiting the category to 431 
C5 to C13 analogues assures that the impact of bioavailability on the toxicokinetic and 432 
toxicodynamic profiles is very limited. Primary alkanols are direct-acting toxicants with a 433 
reversible mode of toxic action described as nonpolar narcosis (i.e., unspecific interaction with 434 
biological membrane in a manner similar to simple anaesthetics). The main route of exposure for 435 
alkanols is oral via rapid gastrointestinal absorption. The majority of an oral dose of any n-436 
alkanol is promptly degraded via simple cellular oxidation; the remainder is eliminated as the 437 
glucuronide conjugate. 438 
Repeated-dose toxicity test results exhibit qualitative consistency in results between and within 439 
species. While protocols vary, results of oral repeated-dose testing exhibit qualitative consistency 440 
between and within mammals. Typical findings are only mild changes including decreased body 441 
weight, slightly increased liver weight, as well as clinical chemical and haematological changes, 442 
but typically without concurrent histopathological effects.  443 
Within ToxCast, the n-alkanols are among the “least promiscuous chemical classes”; < 2.74% of 444 
the ToxCast assays showing any activity and none of the active assay being associated with 445 
specific bioactivity. Screening with in silico profilers reveals that n-alkanols have no predicted 446 
potential of nuclear receptor binding. 447 
This is a category read-across (i.e., many-to-one several times). While several analogues have 448 
been evaluated experimentally in oral repeated-dose testing schemes, the 90-day oral repeated-449 
dose toxicity data and the NOAELs of 1000 mg/kg bw/d for 1-pentanol and1-hexanol is the 450 
conservative prediction. A no systemic toxic conclusion with a NOAEL of 1000 mg/kg bw/d can 451 
be read across with confidence to untested n-alkanols in the C5 to C13 category listed in Table 3. 452 
 453 
6. Acknowledgements 454 
TWS acknowledges funding by the European Cosmetics Association. KRP, ANR, CLM, SEE 455 
and MTDC acknowledge funding from the SEURAT-1 Project, which was funded by the 456 
European Community’s Seventh Framework Programme (FP7/2007-2013) under grant 457 
agreement number 266835 and Cosmetics Europe. Gratitude is expressed to Dr Richard S. 458 
Judson of the U.S. EPA, National Center for Computational Toxicology; Office of Research and 459 
Development for his assistance with the interpretation of the ToxCast data.  460 
 461 
7. References 462 
[1] Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 463 
November 2009 on cosmetic products, replacing Directive 76/768/EC. Off. J. Eur. Union. 464 
L 342: 59-209.  465 
[2] Cronin, M.T.D., Madden, J.C., Enoch S.J., Roberts, D.W., (Eds.), 2013. Chemical Toxicity 466 
Prediction: Category Formation and Read-Across Applications. The Royal Society of 467 
Chemistry, Cambridge UK. 468 
[3] Teubner, W. and Landsiedel, R., 2015. Read-across for hazard assessment: The ugly 469 
duckling in growing up. ATLA 43: 67-71. 470 
[4] European Chemicals Agency (ECHA). 2012. Practical Guide 6 — How to report read 471 
across and categories [ECHA-10-B-11.1-EN]. 32pp. European Chemicals Agency, 472 
Helsinki, Finland. 473 
[5] Przybylak, K.R., Schultz, T.W., Richarz, A.-N., Mellor, C.L., Escher, S.E., and Cronin, 474 
M.T.D. 2016. Read-across of 90-day rat oral repeated-dose toxicity: A case study for 475 
selected β-olefinic alcohols. Computational Toxicology (in press). 476 
[6] Fang, Z., Ionescu, P., Chortkoff, B.S., Kandel, L., Sonner, J., Laster, M.J. and Eger, E.I. 477 
1997. Anesthetic potencies of n-alkanols: Results of additivity and solubility studies 478 
suggest a mechanism of action similar to that for conventional inhaled anesthetics. Anesth. 479 
Analgesia 84: 1042-1048. 480 
[7] McKim, J.M., Bradbury, S.P. and Niemi, G.J. 1987. Fish acute toxicity syndromes and their 481 
use in the QSAR approach to hazard assessment. Environ. Health Perspect. 71: 171-186. 482 
[8] Koleva, Y.K., Cronin, M.T., Madden, J.C. and Schwöbel, J.A. 2011. Modelling acute oral 483 
mammalian toxicity. 1. Definition of a quantifiable baseline effect. Toxicol. In Vitro 25: 484 
1281-1293. 485 
[9] Veith, G.D., Petkova, E.P. and Wallace, K.B. 2009. A baseline inhalation toxicity model for 486 
narcosis in mammals. SAR QSAR Environ. Res. 20: 567-578. 487 
[10] McCreery, M.J. and Hunt, W.A. 1978. Physico-chemical correlates of alcohol intoxication. 488 
Neuropharmacology 17: 451-461. 489 
[11] McKarns, S.C., Hansch, C., Caldwell, W.S., Morgan, W.T., Moore, S.K. and Doolittle, 490 
D.J. 1997. Correlations between hydrophobicity of short-chain aliphatic alcohols and their 491 
ability to alter plasma membrane integrity. Fundam. Applied Toxicol. 36: 62-70. 492 
[12] Strubelt, O., Deters, M., Pentz, R., Siegers, C.-P. and Younes, M. 1999. The toxic and 493 
metabolic effects of 23 aliphatic alcohols in the isolated perfused rat liver. Toxicol. Sci. 49: 494 
133-142. 495 
[13] Pringle, M.J., Brown, K.B. and Miller, K.W. 1981. Can the lipid theories of anesthesia 496 
account for the cutoff in anesthetic potency in homologous series of alcohols? Mol. 497 
Pharmacol. 19: 49-55. 498 
[14] Voet, D. and Voet, J.G. 1990. Biochemistry. John Wiley & Sons, New York. 499 
[15] Kamil, I.A., Smith, J.N. and Williams, R.T. 1953. Studies in detoxication. 46. The 500 
metabolism of aliphatic alcohols. The glucuronic acid conjugation of acyclic aliphatic 501 
alcohols. Biochem. J. 53: 129-136. 502 
[16] Voskoboinikova, V.B. 1966. Substantiation of the maximum permissible concentration of 503 
the flotation reagent IM-68 and its component alcohols (hexyl-, heptyl- and octyl) in water 504 
reservoirs. Hyg. Sanit. (GUS) 31: 310-315. 505 
[17] Opdyke, D.L. 1973. Monographs on fragrance raw materials. Food Cosmet. Toxicol. 11: 506 
95-115. 507 
[18] Patocka, J. and Kuca, K. 2012. Toxic alcohols: Aliphatic saturated alcohols. Mil. Med. Sci. 508 
Lett. (Voj. Zdrav. Listy) 81: 142-163. 509 
[19] ECB (European Chemicals Bureau) 2000. IUCLID Dataset, Pentan-1-ol (71-41-0) (2000 510 
CD-ROM edition). 511 
[20] Butterworth, K.R., Gaunt, I.F., Heading, C.E., Grasso, P. and Gangolli, S.D. 1976. Short-512 
term toxicity of n-amylalcohol in rats. Food Cosmet. Toxicol. 16: 203-207. 513 
[21] ECHA CHEM A 1-pentanol: http://www.echa.europa.eu/web/guest/registration-dossier/-514 
/registered-dossier/2115 (accessed 27.01.2016). 515 
[22] ITII (International Technical Information Institute) 1988. Toxic and Hazardous Industrial 516 
Chemicals Safety Manual. Tokyo, Japan. 517 
[23] ECHA CHEM B 1-hexanol: http://www.echa.europa.eu/web/guest/registration-dossier/-518 
/registered-dossier/13265 (accessed 27.01.2016). 519 
[24] Bingham, E., Cohrssen, B., and Powell, C.H. 2001. Patty's Toxicology Volumes 1-9 5th 520 
ed. John Wiley & Sons. New York, N.Y. p. 6:440 521 
[25] Truhaut, R. 1974. Contribution à l'étude toxicologique de l'alcool heptylique. Archives des 522 
maladies professionelles de médecine du travail, 35: 501-509. 523 
[26] ECH CHEM C 1-heptanol:  http://www.echa.europa.eu/web/guest/registration-dossier/-524 
/registered-dossier/5921/7/1 (accessed 27.01.2016). 525 
[27] ECHA CHEM D 1-octanol: http://www.echa.europa.eu/web/guest/registration-dossier/-526 
/registered-dossier/15210 (accessed 27.01.2016). 527 
[28] Lewis, R.J. Sr. (ed) 2004a. Sax's Dangerous Properties of Industrial Materials. 11th 528 
Edition. Wiley-Interscience, Wiley & Sons, Inc. Hoboken, NJ. p. 1077. 529 
[29] Verschueren, K. 2001. Handbook of Environmental Data on Organic Chemicals. Volumes 530 
1-2. 4th ed. John Wiley & Sons. New York, NY. p. 2164. 531 
[30] ECHA CHEM E 1-undecanol; http://www.echa.europa.eu/web/guest/registration-dossier/-532 
/registered-dossier/2096 (accessed 27.01.2016). 533 
[31] ECHA CHEM F1-dodecanol: I http://www.echa.europa.eu/web/guest/registration-dossier/-534 
/registered-dossier/15424 (accessed 27.01.2016). 535 
[32] Organization for Economic Co-Operation and Development (OECD) and Screening 536 
Information Datasets (SIDS) 2006. High Production Volume Chemicals 1-Dodecanol (Cas 537 
No.: 112-53-83). Processed by United Nations Environmental Program (UNEP). Available 538 
from http://www.inchem.org/documents/sids/sids/112538.pdf. 539 
[33] Raw Material Data Handbook. 1974. Organic Solvents.1: 114. 540 
[34] Organization for Economic Co-Operation and Development (OECD) 2015. Guidance 541 
Document on the Reporting of Integrated Approaches to Testing and Assessment (IATA). 542 
ENV/JM/HA(2015)7. 543 
[35] Schultz, T.W., Amcoff, P., Berggren, E., Gautier, F., Klaric, M., Knight, D. J., Mahony, 544 
C., Schwarz, M., White, A. and Cronin, M.T.D. 2015. A strategy for structuring and 545 
reporting a read-across prediction of toxicity. Reg. Toxicol. Pharmacol. 72: 586-601. 546 
[36] European Chemicals Agency (ECHA) Registered substances. Available from: 547 
https://echa.europa.eu/information-on-chemicals/registered-substances.  548 
[37] Williams, R.T. 1959. The metabolism of some aliphatic aldehydes, ketones and acids. In: 549 
Detoxication mechanisms. The metabolism and detoxication of drugs, toxic substances and 550 
other organic compounds, 2nd Ed., London: Chapman & Hall, Ltd., chapter four, pp. 88-551 
113. 552 
 [38] Moyes, C.D. and Schulte, P.M. 2006. Principles of Animal Physiology. Pearson Benjamin 553 
Cummings, San Francisco. p734. 554 
[39] Alifimoff, J., Firestone, L. and Miller, K. 1989. Anaesthetic potencies of primary alkanols: 555 
implications for the molecular dimensions of the anaesthetic site. Br. J. Pharmacol. 96: 9-556 
16. 557 
[40] Edelfors, S. and Ravn-Jonsen, A. 1990. The effects of alcohols in vitro on the nervous cell 558 
membrane measured by changes in the (Ca2+/Mg2+) ATPase activity and fluidity of the 559 
synaptosomal membrane. Pharmacol. Toxicol. 67: 56-60. 560 
 [41] He, J., Fu, L., Wang, Y., Li, J.J., Wang, X.H., Su, L.M., Sheng, L.X. and Zhao, Y.H. 561 
2014. Investigation on baseline toxicity to rats based on aliphatic compounds and 562 
comparison with toxicity to fish: Effect of exposure routes on toxicity. Reg. Toxicol. 563 
Pharmacol. 70: 98-106. 564 
[42] Veith, G.D., Call, D.J. and Brooke, L.T. 1983. Structure-toxicity relationships for the 565 
fathead minnow, Pimpehales promelas: narcotic industrial chemicals. Can. J. Fish. Aquat. 566 
Sci. 40: 743-748. 567 
[43] Raevsky, O.A., Grigorev, V.Y., Weber, E.E. and Dearden, J.C. 2008. Classification and 568 
quantification of the toxicity of chemicals to guppy, fathead minnow and rainbow trout: 569 
Part 1. Nonpolar narcosis mode of action. QSAR Comb. Sci. 27: 1274–1281. 570 
[44] Schultz, T.W., Seward-Nagel, J., Foster, K.A. and Tucker, V.A. 2004. Structure-activity 571 
relationships for aliphatic alcohols and aquatic toxicity to Tetrahymena. Environ. Toxicol. 572 
19: 1-10. 573 
[45] Schultz, T.W., Sinks, G.D. and Bearden, A.P. 1998. QSARs in aquatic toxicology: A 574 
mechanism of action approach comparing toxic potency to Pimephales promelas, 575 
Tetrahymena pyriformis, and Vibrio fischeri. In: Devillers, J. (ed.) Comparative QSAR. 576 
Taylor and Francis, London, pp. 52-109. 577 
[46] Benane, S.G., Richard, A.M., Blackman, C.F. and Lytle, C.D. 1993. Quantitative 578 
structure-toxicity relationships for a series of primary alcohols in a mammalian viral host 579 
cell reactivation assay. In Vitro Toxicol. 6: 267-277. 580 
[47] US EPA ToxCast 2014. US EPA website with access to the ToxCast data. 581 
https://www.epa.gov/chemical-research/toxicity-forecasting (accessed 16.06.2016).  582 
[48] Richard, A.M., Judson, R.S., Houck, K.A., Grulke, C.M., Volarath, P., Thillainadarajah, I., 583 
Chihae Yang, C., Rathman, J., Martin, M.T., Wambaugh, J.T., Knudsen, T.B., Kancherla, 584 
J., Mansouri, K. Patlewicz, G., Williams, A.J., Little, S.B., Crofton, K.M. and Thomas, 585 
R.S. 2016. ToxCast chemical landscape: Paving the road to 21st century toxicology. Chem. 586 
Res. Toxicol. 29: 1225–1251. 587 
[49] Mellor, C.L, Steinmetz, F.P, Cronin, M.T.D. 2016. Using molecular initiating events to 588 
develop a structural alert based screening workflow for nuclear receptor ligands associated 589 
with hepatic steatosis. Chem. Res. Toxicol. 29: 203-212. 590 
[50] Judson, R.S., Houck, K.A., Kavlock, R.J., Knudsen, T.B., Martin, M.T., Mortensen, H.M., 591 
Reif, D.M., Richard, A.M., Rotroff, D.M., Shah, I. and Dix, D.J. 2010. Predictive in vitro 592 
screening of environmental chemicals – The ToxCast project. Environ. Health 593 
Perspect.118:485-492. 594 
[51] Berggren, E., Amcoff, P., Benigni, R., Blackburn, K. Carney, E. Cronin, M., Deluyker, H., 595 
Gautier, F., Judson, R.S., Kass, G.E.N., Keller, D., Knight, D., Lilienblum, W., Mahony, 596 
C., Rusyn, I., Schultz, T., Schwarz, M., Schüürman, G., White, A., Burton, J., Lostia, A., 597 
Munn, S., and Worth, A. 2015. Chemical safety assessment using read-across: How can 598 
novel testing methods strengthen evidence base for decision-making? Environ. Health 599 
Perspect. 123: 1232–1240. 600 
 601 
33 
 
Supplementary material 
 
 
Read-Across of 90-day Rat Oral Repeated-Dose Toxicity: A Case Study for Selected n-Alkanols 
 
 
Tables for Assessing Similarity of Analogues and Category Members for Read-Across 
  
34 
 
Table 1: Comparison of Substance Identification, Structure and Chemical Classifications 
ID Name CAS No SMILES 2D Structure Molecular Formula 
1 
1-Pentanol 
71-41-0 CCCCCO  C5H12O 
2 
1-Hexanol 
111-27-3 CCCCCCO 
 
C6H14O 
3 1-Heptanol 111-70-6 CCCCCCCO  C7H16O 
4 1-Octanol 111-87-5 CCCCCCCCO  C8H18O 
5 1-Nonanol 143-08-8 CCCCCCCCCO 
 
C9H20O 
6 1-Decanol 112-30-1 CCCCCCCCCCO 
 
C10H22O 
7 1-Undecanol 112-42-5 CCCCCCCCCCCO 
 
C11H24O 
8 1-Dodecanol 112-53-8 CCCCCCCCCCCCO  C12H26O 
9 1-Tridecanol 112-70-9 CCCCCCCCCCCCCO 
 
C13H28O 
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Table 2: Comparison of Physico-Chemical and Molecular Properties1 
ID Name 
Molecular 
Weight 1 
Log 
Kow1a 
Vapour 
Pressure 
(Pa, 25 deg 
C) 1b 
Density 2 
(g/cm3) 
Melting 
Point (deg 
C) 1b 
Water 
Solubility 
(mg/L, 25 
deg C) 1c 
Boiling 
Point (deg 
C) 1b 
pKa 3 
1 1-Pentanol 
88.15 
1.33 
1.51 (M) 
353 
293 (M) 
0.8±0.1 
-49.96 
-78.9 (M) 
20890 
22000 (M) 
136.95 
137.9 (M) 
15.24 
2 1-Hexanol 
102.18 
1.82 
2.03 (M) 
117 
124 (M) 
0.8±0.1 
-37.86 
-44.6 (M) 
6885 
5900/6260 
(M) 
159.09 
157.6 (M) 
15.38 
3 
1-Heptanol 116.21 
2.31 
2.62 (M) 
39.8 
31.2 (M) 
0.8±0.1 
-26.03 
-34 (M) 
1940 
1670/1800 
(M) 
180.33 
176.4 (M) 
15.38 
4 
1-Octanol 130.23 
2.81 
3.00 (M) 
13.2 
10.6 
0.8±0.1 
-14.46 
-15.5 (M) 
814 
540 (M) 
200.67 
195.1 (M) 
15.27 
5 
1-Nonanol 144.26 
3.30 
3.77 (M) 
4.38 
3.03 (M) 
0.8±0.1 
-3.15 
-5 (M) 
156.8 
140 (M) 
220.09 
213.3 (M) 
15.22 
6 
1-Decanol 158.29 
3.79 
4.57 (M) 
1.45 
1.13 (M) 
0.8±0.1 
7.89 
6.9 (M) 
28.21 
37 (M) 
238.62 
231.1 (M) 
15.21 
7 
1-Undecanol 172.31 
4.28 
 
0.68 
0.396 (M) 
0.8±0.1 
18.67 
19 (M) 
43.04 
 
256.24 
243 (M) 
15.2 
8 
1-Dodecanol 186.34 
4.77 
5.13 (M) 
0.242 
0.113 (M) 
0.8±0.1 
29.19 
24 (M) 
6.898 
4 (M) 
272.96 
259 (M) 
15.2 
9 
1-Tridecanol 200.37 5.26 
0.0316 
0.0581(M) 
0.8±0.1 
0.0316 
 
4.533 
288.77 
152 (M) 
15.2 
M = measured value 
1Values typically derived from EPISuite v4.1, a KOWWIN Program (v1.68), b MPBPWIN v1.43, c at 25 deg C; (mg/L) Kow (WSKOW v1.42); 2 
ACD/Lab Percepta Platform - PhysChem Module (from ChemSpider); 3 Predicted by PERCEPTA; predicted by ACD (Advanced Chemistry 
Development Inc., Toronto, Canada) 
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Table 3: Comparison of Substituents, Functional Groups, and Extended Structural Fragments 
ID Name Key Substituent(s) 
Functional 
Group(s) 
Extended 
Fragment(s) 
Chemical Class: 
Chemical Sub-
Class: 
1 1-Pentanol 
-OH -CH3, -CH2- – saturated aliphatic alcohols straight-chain 
2 1-Hexanol 
-OH -CH3, -CH2- – saturated aliphatic alcohols straight-chain 
3 
1-Heptanol -OH -CH3, -CH2- – saturated aliphatic alcohols straight-chain 
4 
1-Octanol -OH -CH3, -CH2- – saturated aliphatic alcohols straight-chain 
5 
1-Nonanol -OH -CH3, -CH2- – saturated aliphatic alcohols straight-chain 
6 
1-Decanol -OH -CH3, -CH2- – saturated aliphatic alcohols straight-chain 
7 
1-Undecanol -OH -CH3, -CH2- – saturated aliphatic alcohols straight-chain 
8 
1-Dodecanol -OH -CH3, -CH2- – saturated aliphatic alcohols straight-chain 
9 
1-Tridecanol -OH -CH3, -CH2- – saturated aliphatic alcohols straight-chain 
 
 
 
 
 
 
 
Table 4: Comparison of Abiotic Transformation and Toxicokinetics 
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ID Name 
Abiotic 
Transformation 
Toxicokinetics 
Absorptio
n 
Bioavailability half-life  Elimination 
1 1-Pentanol      
2 1-Hexanol Phototransformat
ion in air - half-
life: 30.8 hrsc 
   Rabbit:10.3% as hexyl 
glucuronidee 
3 1-Heptanol Phototransformat
ion in air - half-
life: 28.1c 
   Rabbit: 5.3% as heptyl 
glucuronidee 
4 1-Octanol Phototransformat
ion in air - half-
life: 26.7 hrsd 
orally 
rapidly 
absorbeda,b 
>80%a,b  mainly as CO2,  small amount 
as n-octyl glucuronidea,b; 
Rabbit: 9.5% as octyl 
glucuronidee 
5 1-Nonanol     Rabbit: 4.1% as nonyl 
glucuronidee 
6 1-Decanol     Rabbit: 3.5% as decyl 
glucuronidee 
7 1-Undecanol      
8 1-Dodecanol      
9 1-Tridecanol      
aWilliams, R.T. 1959. The metabolism of some aliphatic aldehydes, ketones and acids. In: Detoxication mechanisms. The metabolism and 
detoxication of drugs, toxic substances and other organic compounds, 2nd Ed., London: Chapman & Hall, Ltd., chapter four, pp. 88-113; 
bOpdyke, D.L. 1973. Monographs on fragrance raw materials. Food Cosmet. Toxicol. 11: 95-115; cKwok, E.S.C. and Atkinson, R.,1994. Gas-
phase atmospheric chemistry of dibenzo-pdioxin and dibenzofuran. Environ.Sci.Technol. 28:528-533; dAtkinson, R. 1994. Gas-phase 
tropospheric chemistry of organic compounds. J. Phys. Chem. Ref. Data, Monograph 2:1-216.  eKamil, I.A., Smith, J.N. and Williams, R.T. 1953. 
Studies in detoxication. 46. The metabolism of aliphatic alcohols. The glucuronic acid conjugation of acyclic aliphatic alcohols. Biochem. J. 53: 129-136. 
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Table 5: Comparison of Potential Metabolic Products 
ID Name 
Liver metabolism simulator Toolbox 
v3.3 
MetaPrint2D-React 
software 
SMARTCyp 
version 2.4.2 
Meteor Nexus 
Rat liver S9 Skin metabolism 
1 1-Pentanol Hydroxylation (1) 
Oxidation (1) 
Hydroxylation (2) Hydroxylation 
Oxidation 
Acylation 
Dehydroxylation 
Methylation 
Alkylation 
Dealkylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (3) 
Oxidation (1) 
beta-Oxidation of 
Carboxylic Acids (1) 
 
2 1-Hexanol Hydroxylation (1) 
Oxidation (1) 
Hydroxylation (2) Hydroxylation 
Oxidation 
Acylation 
Dehydroxylation 
Methylation 
Alkylation 
Dealkylation 
Dehydration 
Demethylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (3) 
Oxidation (1) 
beta-Oxidation of 
Carboxylic Acids (1) 
 
3 
1-Heptanol 
Hydroxylation (1) 
Oxidation (1) 
Hydroxylation (2) Hydroxylation 
Oxidation 
Acylation 
Dehydroxylation 
Methylation 
Alkylation 
Dealkylation 
Dehydration 
Demethylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (3) 
Oxidation (1) 
 
4 
1-Octanol 
Hydroxylation (2) 
Oxidation (1) 
Hydroxylation (2) Hydroxylation 
Oxidation 
Acylation 
Dehydroxylation 
Methylation 
Alkylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (3) 
Oxidation (1) 
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ID Name 
Liver metabolism simulator Toolbox 
v3.3 
MetaPrint2D-React 
software 
SMARTCyp 
version 2.4.2 
Meteor Nexus 
Rat liver S9 Skin metabolism 
Dealkylation 
Dehydration 
Demethylation 
5 
1-Nonanol 
Hydroxylation (2) 
Oxidation (1) 
Hydroxylation (2) Hydroxylation 
Oxidation 
Acylation 
Dehydroxylation 
Methylation 
Alkylation 
Dealkylation 
Dehydration 
Demethylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (3) 
Oxidation (1) 
 
6 
1-Decanol 
Hydroxylation (2) 
Oxidation (1) 
Hydroxylation (2) Hydroxylation 
Oxidation 
Acylation 
Dehydroxylation 
Methylation 
Alkylation 
Dealkylation 
Dehydration 
Demethylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (3) 
Oxidation (1) 
 
7 
1-Undecanol 
Hydroxylation (2) 
Oxidation (1) 
Hydroxylation (2) Hydroxylation 
Oxidation 
Acylation 
Dehydroxylation 
Methylation 
Alkylation 
Dealkylation 
Dehydration 
Demethylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (3) 
Oxidation (1) 
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ID Name 
Liver metabolism simulator Toolbox 
v3.3 
MetaPrint2D-React 
software 
SMARTCyp 
version 2.4.2 
Meteor Nexus 
Rat liver S9 Skin metabolism 
8 
1-Dodecanol 
Hydroxylation (2) 
Oxidation (1) 
Hydroxylation (2) Hydroxylation 
Oxidation 
Acylation 
Dehydroxylation 
Methylation 
Alkylation 
Dealkylation 
Dehydration 
Demethylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (3) 
Oxidation (1) 
 
9 
1-Tridecanol 
Hydroxylation (2) 
Oxidation (1) 
Hydroxylation (2) Hydroxylation 
Oxidation 
Acylation 
Dehydroxylation 
Methylation 
Alkylation 
Dealkylation 
Dehydration 
Demethylation 
Possible sites of 
metabolism have 
been identified 
Hydroxylation (3) 
Oxidation (1) 
 
 
() - The number of metabolites for specific transformation. 
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Table 6: Comparison of Toxicophores 
ID Name Toxicophores1 DNA binding by 
OECD1 
Protein 
binding by 
OECD1 
Nuclear receptor 
binding2 
Liver& 
Mitochondria 
toxicity2 
1 1-Pentanol 
Cramer Class I No alert No alert 
Inactive 
No alert 
2 1-Hexanol 
Cramer Class I No alert No alert Inactive No alert 
3 
1-Heptanol Cramer Class I No alert No alert Inactive No alert 
4 
1-Octanol Cramer Class I No alert No alert Inactive No alert 
5 
1-Nonanol Cramer Class I No alert No alert Inactive No alert 
6 1-Decanol Cramer Class I No alert No alert Inactive No alert 
7 
1-Undecanol Cramer Class I No alert No alert Inactive No alert 
8 
1-Dodecanol Cramer Class I No alert No alert Inactive No alert 
9 
1-Tridecanol Cramer Class I No alert No alert Inactive No alert 
1 OECD QSAR Toolbox 3.3. 2 COSMOS profilers available via COSMOS space: http://cosmosspace.cosmostox.eu 
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Table 7: Comparison of Mechanistic Plausibility and Adverse Outcome Pathway-Related Event Data 
ID Name 
Mechanistic 
Plausibility 
Adverse 
Outcome 
Pathway or 
Mode of Toxic 
Action: 
Molecular 
Initiating 
Event: 
Key Event 1 
etc.: 
Key Event 
Relationship 1 
etc.: 
Other 
Mechanistically-
Relevant Events 
1 1-Pentanol  
narcosis - 
depressant 
anesthesia 
unspecific 
interactions 
with biological 
membranes 
   
2 1-Hexanol  narcosis - 
depressant 
anesthesia 
unspecific 
interactions 
with biological 
membranes 
  CNS depression 
3 
1-Heptanol 
 narcosis - 
depressant 
anesthesia 
unspecific 
interactions 
with biological 
membranes 
   
4 
1-Octanol 
 narcosis - 
depressant 
anesthesia 
unspecific 
interactions 
with biological 
membranes 
  CNS depression 
biphasic effect 
on the ATPase 
activity 
5 
1-Nonanol 
 narcosis - 
depressant 
anesthesia 
unspecific 
interactions 
with biological 
membranes 
   
6 
1-Decanol 
 narcosis - 
depressant 
anesthesia 
unspecific 
interactions 
with biological 
membranes 
  biphasic effect 
on the ATPase 
activity 
7 
1-Undecanol 
 narcosis - 
depressant 
anesthesia 
unspecific 
interactions 
with biological 
membranes 
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ID Name 
Mechanistic 
Plausibility 
Adverse 
Outcome 
Pathway or 
Mode of Toxic 
Action: 
Molecular 
Initiating 
Event: 
Key Event 1 
etc.: 
Key Event 
Relationship 1 
etc.: 
Other 
Mechanistically-
Relevant Events 
8 
1-Dodecanol 
 narcosis - 
depressant 
anesthesia 
unspecific 
interactions 
with biological 
membranes 
  stimulation of the 
ATPase activity 
9 
1-Tridecanol 
 narcosis - 
depressant 
anesthesia 
unspecific 
interactions 
with biological 
membranes 
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Table 8: Comparison of Toxicologically Relevant In Vivo, In Vitro and Ex Vivo Data 
Name 
1
-P
en
ta
n
o
l 
1
-H
ex
a
n
o
l 
1
-H
ep
ta
n
o
l 
1
-O
ct
a
n
o
l 
1
-N
o
n
a
n
o
l 
1
-D
ec
a
n
o
l 
1
-U
n
d
ec
a
n
o
l 
1
-D
o
d
ec
a
n
o
l 
1
-T
ri
d
ec
a
n
o
l 
Endpoint: 
NOAEL (Repeat 
dose toxicity) 
1000 
(mg/kg 
bw/d) 
1127 
mg/kg 
bw/d for 
male and 
1243 
mg/kg 
bw/d for 
female 
1000 
(mg/kg 
bw/d) 
  
    2000 
(mg/kg 
bw/d) 
2000 
(mg/kg 
bw/d) 
  
[1] [3] [39]       [9] [11]   
Endpoint: NOEL 
(Repeat dose 
toxicity) 
> 6400 
(mg/m3) 
    1300 
(mg/kg 
bw/d) 
    <100 
(mg/kg 
bw/d) 
100 (mg/kg 
bw/d) 
  
[2]     [4,58]     [9] [10]   
Endpoint: 
LOAEL (Repeat 
dose toxicity) 
  1000 
(mg/kg 
bw/d) 
              
  [3]               
Endpoint: HNEL 
(Repeat dose 
toxicity) 
882 (mg/kg 
bw/d) 
  50 (mg/kg 
bw/d) 
130 (mg/kg 
bw/d) 
          
[4]   [6] [7]           
Endpoint: LEL 
(Repeat dose 
toxicity) 
5080 
(mg/kg 
bw/d) 
    650-2564 
(mg/kg 
bw/d) 
      3324 
(mg/kg 
bw/d) 
  
[5]     [7,8]       [12]   
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Name 
1
-P
en
ta
n
o
l 
1
-H
ex
a
n
o
l 
1
-H
ep
ta
n
o
l 
1
-O
ct
a
n
o
l 
1
-N
o
n
a
n
o
l 
1
-D
ec
a
n
o
l 
1
-U
n
d
ec
a
n
o
l 
1
-D
o
d
ec
a
n
o
l 
1
-T
ri
d
ec
a
n
o
l 
Endpoint: LOEL 
(Repeat dose 
toxicity) 
              100-2000 
(mg/kg/d) 
  
              [13]   
Endpoint: 
NOAEL 
(Reproductive 
toxicity) 
1000 
(mg/kg/d 
                
[1]                 
Endpoint: 
NOAEL 
(Teratogenicity) 
  370-1240 
(mg/kg/d) 
  1300 
(mg/kg/d) 
        
  [3]   [16]         
Endpoint: 
NOAEC 
(Teratogenicity) 
14 (mg/L 
air) 
3.5 (mg/L 
air) 
      >100(mg/L 
air) 
      
[15] [3]       [61]       
Endpoint: 
LOAEL 
(Maternal 
toxicity) 
      130 
(mg/kg/d) 
  130 
(mg/kg/d) 
      
      [17]   [61]       
Endpoint: 
NOAEC 
(Maternal 
toxicity) 
      >0.4 
(mg/L) 
 
 
[16]   
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Name 
1
-P
en
ta
n
o
l 
1
-H
ex
a
n
o
l 
1
-H
ep
ta
n
o
l 
1
-O
ct
a
n
o
l 
1
-N
o
n
a
n
o
l 
1
-D
ec
a
n
o
l 
1
-U
n
d
ec
a
n
o
l 
1
-D
o
d
ec
a
n
o
l 
1
-T
ri
d
ec
a
n
o
l 
Endpoint: 
Carcinogenic/ 
Genotoxicity  
1 X 
Negative 
5 x 
Negative 
  2 X 
Negative 
    1 X 
Negative 
7X 
Negative  
1x Positive 
  
[66] [3]   [16]     [9] [19-25]   
Endpoint: LC50 
(Acute toxicity) 
  >21 (mg/L 
air) 
>21 (mg/ 
L/hour) 
          >700 
(mg/m3) 
 
 
    
  >5030 
(mg/L air) 
              
  [3, 35]         [9]      
Endpoint: LD50 
(Acute toxicity) 
 
From different 
routes of 
exposure 
140-4585 
(mg/kg/)  
2.83-5.66 
(mL/kg) 
103-4870 
(mg/kg) 
500-6200 
(mg/kg) 
1790 - 
≥5000 
(mg/kg) 
 
 
800-6400  
(mg/kg) 
44 
(mmol/kg) 
 
5660 
(uL/kg) 
1000-5000 
mg/kg  
3000-> 
15800 
(mg/kg) 
 
 
1500-
>26530 
(mg/kg/d) 
>12.8 - > 
36 (ml/kg) 
 
 
5600-
17200 
(mg/kg) 
[14, 27-31, 
34,54-55, 
66] 
[3, 36-38] [37, 39-41, 
67] 
[16,42,43] [44-46,55, 
59,60] 
[18, 61, 68 
] 
[9, 62, 69] [11,47,63,6
4] 
[48] 
Endpoint: LDLo  
(Acute toxicity) 
122-
2000(mg/k
g) 
                
[32,33,57]                 
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Name 
1
-P
en
ta
n
o
l 
1
-H
ex
a
n
o
l 
1
-H
ep
ta
n
o
l 
1
-O
ct
a
n
o
l 
1
-N
o
n
a
n
o
l 
1
-D
ec
a
n
o
l 
1
-U
n
d
ec
a
n
o
l 
1
-D
o
d
ec
a
n
o
l 
1
-T
ri
d
ec
a
n
o
l 
Endpoint: 
Genotoxicity 
(AMES, 
Chromosomal 
abrration, gene 
mutation) 
2 x 
Negative 
1 x 
Negative 
1 x 
Negative 
1 x 
Negative 
  2 x 
Negative 
     
[52,57] [3] [39] [50]   [26, 51]      
Toxcast overview 
[53] 
- 
250 (1 
active) 
250 (10 
active) 
602 (0 
active) 
150 (4 
active) 
257(15 
active) 
602 (25 
active) 
602 (3 
active) 
602 (30 
active) 
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